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Abstract
Background
Information regarding the safety and efficacy of  artemisinin combination treatments for malaria in pregnant women is limited, particularly 
among women who live in sub-Saharan Africa.
Methods
We conducted a multicenter, randomized, open-label trial of  treatments for malaria in pregnant women in four African countries. A 
total of  3428 pregnant women in the second or third trimester who had falciparum malaria (at any parasite density and regardless 
of  symptoms) were treated with artemether–lumefantrine, amodiaquine–artesunate, mefloquine–artesunate, or dihydroartemisinin–
piperaquine. The primary end points were the polymerase-chain-reaction (PCR)–adjusted cure rates (i.e., cure of  the original infection; 
new infections during follow-up were not considered to be treatment failures) at day 63 and safety outcomes.
Results
The PCR-adjusted cure rates in the per-protocol analysis were 94.8% in the artemether–lumefantrine group, 98.5% in the amodiaquine–
artesunate group, 99.2% in the dihydroartemisinin–piperaquine group, and 96.8% in the mefloquine–artesunate group; the PCR-adjusted 
cure rates in the intention-to-treat analysis were 94.2%, 96.9%, 98.0%, and 95.5%, respectively. There was no significant difference 
among the amodiaquine–artesunate group, dihydroartemisinin–piperaquine group, and the mefloquine–artesunate group. The cure rate 
in the artemether–lumefantrine group was significantly lower than that in the other three groups, although the absolute difference was 
within the 5-percentage-point margin for equivalence. The unadjusted cure rates, used as a measure of  the post-treatment prophylactic 
effect, were significantly lower in the artemether–lumefantrine group (52.5%) than in groups that received amodiaquine–artesunate 
(82.3%), dihydroartemisinin–piperaquine (86.9%), or mefloquine–artesunate (73.8%). No significant difference in the rate of  serious 
adverse events and in birth outcomes was found among the treatment groups. Drug-related adverse events such as asthenia, poor 
appetite, dizziness, nausea, and vomiting occurred significantly more frequently in the mefloquine–artesunate group (50.6%) and the 
amodiaquine–artesunate group (48.5%) than in the dihydroartemisinin–piperaquine group (20.6%) and the artemether–lumefantrine 
group (11.5%) (P<0.001 for comparison among the four groups).
Conclusions
Artemether–lumefantrine was associated with the fewest adverse effects and with acceptable cure rates but provided the shortest post-
treatment prophylaxis, whereas dihydroartemisinin–piperaquine had the best efficacy and an acceptable safety profile. (Funded by the 
European and Developing Countries Clinical Trials Partnership and others; ClinicalTrials.gov number, NCT00852423.)
Introduction
Malaria during pregnancy is a major public health problem in 
countries where the disease is endemic.1 In areas in which the 
intensity of  transmission is moderate to high and does not 
vary substantially from year to year, most malaria infections 
during pregnancy remain asymptomatic but increase the risk 
of  maternal anemia and low birth weight, the latter of  which 
is associated with increased infant mortality.2 In areas where 
the intensity of  transmission is low and varies substantially 
between years, symptomatic malaria and severe disease can 
develop in pregnant women, with an associated increased 
risk of  fetal loss and maternal death.2 Considering the 
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harmful effects of  malaria during pregnancy, it is extremely 
important to treat the disease adequately with efficacious 
medicines. However, little information is available regarding 
the pharmacokinetics, safety, and efficacy of  new antimalarial 
agents in pregnant women3-5 because pregnant women are 
systematically excluded from regulatory trials.
For women in the second or third trimester of  pregnancy, 
World Health Organization (WHO) guidelines recommend 
a 3-day course with either an artemisinin-based combination 
therapy that is known to be effective in the country or region 
or clindamycin plus a 7-day course of  either artesunate or 
quinine.6 Although the experience regarding the use of  
artemisinin-based combination therapies in pregnancy is 
increasing,6 this information is still limited, particularly in 
sub-Saharan Africa.
Methods
Trial design
We conducted this randomized, open-label trial from 
June 2010 through August 2013 at seven sites in four sub-
Saharan African countries: Burkina Faso (two sites), Ghana 
(three), Malawi (one), and Zambia (one). The trial protocol, 
which is available with the full text of  this article at NEJM.
org, has been described in detail elsewhere.7 In brief, 
pregnant women in the second or third trimester who had 
a Plasmodium falciparum monoinfection of  any density, 
regardless of  symptoms, a hemoglobin level of  7 g per 
deciliter or more, and no other serious illness were recruited 
into the trial and randomly assigned to one of  the following 
four treatments: artemether–lumefantrine, amodiaquine–
artesunate, mefloquine–artesunate, or dihydroartemisinin–
piperaquine.
Sigma-Tau Industrie Farmaceutiche Riunite donated 
dihydroartemisinin–piperaquine, Novartis donated 
artemether–lumefantrine, and Sanofi-Aventis donated 
artesunate–amodiaquine. The Drugs for Neglected Diseases 
Initiative facilitated the negotiation for the procurement 
of  artesunate–mefloquine from Farmanguinhos, which 
donated the treatment. The donors did not have any role 
in reviewing the protocol or the manuscript, although the 
protocol synopsis was provided to the manufacturers.
The trial was set up in a pragmatic approach with three 
treatment groups per country with the use of  a balanced, 
incomplete block design, which allowed for the maximized 
use of  resources and took into account the policies regarding 
antimalarial treatment in the respective countries (Table S1 
in the Supplementary Appendix, available at NEJM.org). All 
doses of  the study drugs were given under direct observation 
on days 0, 1, and 2 and according to the recommendations of  
the manufacturer (Table S2 in the Supplementary Appendix). 
At recruitment, the gestational age was estimated with the 
use of  the symphysiofundal height, and the fetal viability 
was assessed by means of  ultrasonography with a portable 
multipurpose machine.
Follow-up
After completion of  the 3-day treatment, patients were 
asked to return to the clinic (in Ghana, patients were visited 
at home) for follow-up visits on days 3 and 7 and then once 
every week until day 63. At each visit, a medical history was 
obtained, and information was collected regarding current 
signs and symptoms, including the start and end date, the 
severity (mild, moderate, severe, or life-threatening), and 
the perceived relationship to the study treatment (definitely 
unrelated, unlikely to be related, possibly related, probably 
related, or definitely related), as well as the outcome of  any 
adverse events. A blood sample was obtained for malaria 
smears and dried blood spots for later genotyping, for 
full blood counts (on days 7, 14, 28, and 63 only), and for 
measurement of  the total bilirubin, alanine aminotransferase, 
and creatinine levels (on days 7 and 14 only). Rescue 
treatment for recurrent infection was given according to 
national guidelines.
At the end of  the active follow-up period, women were 
asked to attend the antenatal clinic monthly or when they 
felt unhealthy, until delivery. After delivery, the newborn 
was examined for congenital malformations and weighed, 
and the gestational age was estimated with the use of  the 
total Ballard score (range, −10 [20 weeks of  gestation] to 
50 [44 weeks of  gestation]).8 A placental-biopsy specimen 
was obtained as soon as possible after delivery and was 
preserved in 10% neutral buffered formalin. The biopsy 
specimens were processed and embedded in paraffin wax by 
means of  standard techniques and were kept at 4°C. Paraffin 
sections that were 4 mm thick were stained with hematoxylin 
and eosin and read at the Barcelona Center for International 
Health Research.7
Laboratory procedures
Giemsa-stained thick and thin blood films were read 
independently by two readers. Blood smears with discordant 
results (differences between the two microscopists with 
regard to the diagnosis of  the species, positivity, or parasite 
density of  >50%) were reexamined by a third, independent 
microscopist, and parasite density was calculated by 
averaging the two closest counts. We estimated parasite 
density by counting the number of  asexual parasites per 200 
white cells, assuming a white-cell count of  8000 per cubic 
millimeter. The total bilirubin, alanine aminotransferase, and 
creatinine levels were measured with the use of  the Flexor 
Junior biochemistry analyzer. The full blood count was 
obtained with the use of  the Sysmex XT-2000i hematology 
analyzer. The hemoglobin level was measured with the use 
of  the HemoCue system. For polymerase-chain-reaction 
(PCR) analysis, blood samples were collected on filter papers 
(Whatman 3MM) that were subsequently transported to 
the Institute of  Tropical Medicine, Antwerp, Belgium, 
where centralized genotyping (of  the glutamate-rich protein 
[GLURP] and surface proteins of  the P. falciparum merozoite 
[MSP2 and MSP1]) was performed to distinguish reinfection 
from recrudescence.9 Samples that did not produce a result 
were classified as indeterminate.
Trial end points
The primary end points of  the trial were the PCR-adjusted 
cure rates at day 63 (Table S3 in the Supplementary Appendix) 
and the safety outcomes7 (Table S4 in the Supplementary 
Appendix). In the estimation of  the PCR-adjusted cure 
rate, only recurrent infections that were shown by means 
of  genotyping to be the same infections as those before 
treatment (i.e., recrudescent infections) were considered 
to be treatment failures; conversely, for the estimation of  
the PCR-unadjusted cure rate, all recurrent infections were 
considered to be treatment failures.
Treatment failures were classified as either early or late 
treatment failures, with the latter category comprising late 
clinical failures and late parasitologic failures. Early treatment 
failure was defined as one of  the following: the development 
of  danger signs or severe malaria or worsening of  clinical 
conditions on day 0, 1, 2, or 3 in the presence of  parasitemia; 
http://dx.doi.org/10.1056/NEJMoa1508606
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up or withdrew and those with missing or indeterminate 
results on PCR assay, and an intention-to-treat population 
that included multiple imputations of  data from women 
who were lost to follow-up or withdrew and from those who 
had missing or indeterminate results on PCR assay. The per-
protocol analysis was considered to be the primary analysis 
approach. Persons with major protocol violations, defined as 
a violation of  the inclusion or exclusion criteria, receipt of  a 
treatment different from the randomly assigned one, missing 
at least a full day of  treatment, intake of  other drugs with 
antimalarial activity, and missing day 63 blood smears, were 
excluded from the per-protocol analysis. All the secondary 
end points were analyzed with the use of  an available-data 
approach.
We tested the primary hypothesis by calculating the 95% 
confidence interval for the difference in cure rates. If  the 
difference in true (PCR-adjusted) cure rates was less than 
5 percentage points, the treatments were considered to be 
therapeutically equivalent. This margin was chosen on the 
basis of  the WHO recommendation that a new recommended 
antimalarial treatment that is adopted as policy should have an 
average cure rate of  95% or more as assessed in clinical trials. 
The confidence interval was calculated from a generalized 
linear model with adjustment for differences among the four 
countries. A number of  sensitivity analyses were performed, 
including an analysis with multiple imputation of  missing 
outcomes, a pairwise comparison that was limited to trial 
sites where a head-to-head comparison of  treatments was 
performed, an analysis with adjustment for parasite density, 
gestational age, and gravidity at trial entry, and an analysis of  
the time to treatment failure with the use of  Cox regression 
models. For the safety analysis, all the women who received at 
least one dose of  the study treatment were included. Details 
of  the subgroup analyses are provided in the Supplementary 
Appendix.
Results
Participants
A total of  3428 pregnant women who had P. falciparum 
infection were randomly assigned to receive one of  
four treatment: artemether–lumefantrine (881 women), 
amodiaquine–artesunate (843), dihydroartemisinin–
piperaquine (855), or mefloquine–artesunate (849) (Fig. 1). 
The trial sites in Burkina Faso recruited 870 women, those 
in Ghana 788, the one in Malawi 870, and the one in Zambia 
900. Five women were withdrawn by the investigators 
immediately after starting the treatment because of  protocol 
deviations (3 did not have malaria, 1 was not pregnant, and 1 
had been enrolled previously), although they were included 
in the safety analysis.
The intention-to-treat analysis included 3150 women 
(830 women in the artemether–lumefantrine group, 
791 in the amodiaquine–artesunate group, 759 in the 
dihydroartemisinin–piperaquine group, and 770 in the 
mefloquine–artesunate group). The per-protocol analysis 
included 3000 women (810 women in the artemether–
lumefantrine group, 742 in the amodiaquine–artesunate 
group, 720 in the dihydroartemisinin–piperaquine group, 
and 728 in the mefloquine–artesunate group) (Fig. 1). 
Approximately half  the exclusions from the per-protocol 
analysis (227 of  423 women [53.7%]) were due to loss to 
follow-up, withdrawal, or death.
The characteristics of  the participants at baseline were 
similar among the treatment groups (Table 1). Most women 
parasitemia on day 3 that was the same as or greater than the 
count on day 0; or parasitemia on day 3 and fever (axillary 
temperature, ≥37.5°C). Late clinical failure was defined as 
the either the development of  danger signs or severe malaria 
or worsening of  clinical conditions on any day after day 3 
in the presence of  parasitemia, without the patient having 
previously met any of  the criteria for early treatment failure, 
or the presence of  parasitemia and fever on any day after 
day 3, without the patient having previously met the criteria 
for early treatment failure. Late parasitologic failure was 
defined as the presence of  parasitemia after day 3 and an 
axillary temperature of  less than 37.5ºC, without the patient 
having previously met any of  the criteria of  early treatment 
failure or late parasitologic failure. An adequate clinical 
and parasitologic response was defined as the absence of  
parasitemia at the end of  follow-up (day 63), regardless 
of  the axillary temperature, without the patient having 
previously met any of  the criteria of  early treatment failure 
or late treatment failure.
Adverse events and serious adverse events were recorded and 
monitored throughout the trial by an independent data and 
safety monitoring board. The relationship between treatment 
and adverse events or serious adverse events was determined 
by the local investigator on the basis of  clinical judgment, 
possible alternative causes (e.g., concomitant therapy), time 
of  occurrence relative to the study treatment, and available 
information on the study treatment. The data and safety 
monitoring board reviewed listings of  serious adverse events 
regularly. Secondary end points were PCR-unadjusted cure 
rates (Table S3 in the Supplementary Appendix) at day 63, 
time to treatment failure (PCR-adjusted and PCR-unadjusted) 
(Fig. S1 in the Supplementary Appendix), asexual parasite 
clearance,10 gametocytemia (prevalence and density), and 
changes in the hemoglobin level.
Trial oversight
The contributions of  the authors are listed in Table S5 in 
the Supplementary Appendix. The authors vouch for the 
accuracy and completeness of  the data and for the fidelity 
of  the trial to the protocol. The trial was approved by the 
ethics committee at the Antwerp University Hospital, the 
relevant national or local ethics committees, and the national 
drug regulatory authorities (Table S6 in the Supplementary 
Appendix). All the study participants provided written 
informed consent. If  the woman was illiterate, she would 
provide a fingerprint and a witness would write the name of  
the patient onto the form and sign and date it.
Statistical analysis
The trial was designed to determine whether all four 
treatments had similar PCR-adjusted cure rates (difference, 
<5 percentage points), with 95% power for each of  the six 
pairwise comparisons and 80% power for the combined 
hypothesis that all the treatments would be equivalent.7 
No multiplicity adjustment for the primary analysis was 
performed because the four treatments would be declared 
similar only if  all six pairwise comparisons were shown to be 
within the 5-percentage-point margin. For this joint decision 
rule, no alpha-level correction was needed.11
Data were captured in an electronic case-report form that 
was developed with the use of  MACRO software (Infermed). 
A statistical analysis plan was developed before the database 
lock. For the primary end point, three analysis populations 
were used: a per-protocol population, an intention-to-treat 
population that excluded patients who were lost to follow-
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were included during the second trimester of  pregnancy, 
and primigravidae represented approximately one third of  
the trial population. Parasite density was more than 2000 per 
cubic milliliter in approximately one third of  the women, and 
few women (6.1%) had fever at the time of  recruitment.
Treatment efficacy
The large majority of  treatment failures were late parasitologic 
failures, with fewer women having a late clinical failure (Table 
2). Most cases of  late treatment failures were classified as 
new infections.
According to the per-protocol analysis, the overall PCR-
adjusted cure rate at day 63 was 94.8% (95% confidence 
interval [CI], 93.0 to 96.1; 748 of  789 women) in the 
artemether–lumefantrine group, 98.5% (95% CI, 97.3 to 
99.2; 718 of  729 women) in the amodiaquine–artesunate 
group, 99.2% (95% CI, 98.2 to 99.6; 701 of  707 women) in 
the dihydroartemisinin–piperaquine group, and 96.8% (95% 
CI, 95.2 to 97.9; 693 of  716 women) in the mefloquine–
artesunate group (Table 2, and Fig. S1 in the Supplementary 
Appendix). There was no significant difference among the 
amodiaquine–artesunate group, the dihydroartemisinin–
piperaquine group, and the mefloquine–artesunate group. 
The cure rate in the artemether–lumefantrine group was 
significantly lower than the rate in the other three treatment 
groups (P<0.001), although the difference was within the 
prespecified margin of  5 percentage points (Fig. 2).
The unadjusted cure rates (Table S3 in the Supplementary 
Appendix) were significantly lower in the artemether–
lumefantrine group (52.5%; 425 of  810 women) than in the 
amodiaquine–artesunate group (82.3%; 611 of  742), the 
dihydroartemisinin–piperaquine group (86.9%; 626 of  720), 
and the mefloquine–artesunate group (73.8%; 537 of  728) 
(P<0.001) (Table 2). Country-specific results are provided 
in Table S7 in the Supplementary Appendix. The intention-
to-treat analyses and analyses with multiple imputations of  
unavailable outcomes further supported the efficacy results 
(Table S8 in the Supplementary Appendix). Results from the 
sensitivity analyses were generally consistent with those from 
the primary analyses.
At day 2 after the initiation of  treatment, nearly all the 
women (>99.5%) had a negative blood smear. However, 
parasite clearance was slower among the women treated 
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women (830 women i  the rtemether–lumefan-
trine group, 791 in th amodiaquine–art sunate 
group, 759 in the dihydr artemisinin–pipera-
quine group, and 770 in the mefloquine–artesu-
nate group). The per-protocol analysis included 
3000 women (810 women in the artemether–
lumefantrine group, 742 in the amodiaquine–
artesunate group, 720 in the dihydroartemis-
inin–piperaquine group, and 728 in the 
mefloquine–artesunate group) (Fig. 1). Approxi-
mately half the exclusions from the per-protocol 
analysis (227 of 423 women [53.7%]) wer due to
loss to foll w-up, withdrawal, or death.
The charact ristics of the participants at base-
line were similar among the treatment groups 
(Table 1). Most women were included during the 
second trimester of pregnancy, and primigravi-
dae represented approximately one third of the 
trial population. Parasite density was more than 
2000 per cubic milliliter in approximately one 
Figure 1. Randomization of Patients and the Analysis Populations.
A total of five women were excluded after the receipt of the first dose of study medication because of entry-criteria violations. The exclu-
sions from the intention-to-treat population (blue) and the per-protocol population (yellow-green) are based on the efficacy population. 
The intention-to-treat population excluded women who were lost to follow-up, died, withdrew, or had missing or indeterminate results 
on polymerase-chain-reaction assay; however, these women were included in the intention-to-treat analyses that used multiple imputa-
tions. The per-protocol population also excluded persons with major protocol violations, defined as a violation of the inclusion or exclu-
sion criteria, receipt of a treatment different from the randomly assigned one, missing at least a full day of treatment, intake of other 
drugs with antimalarial activity, and missing day 63 blood smears.
8358 Patients were assessed for eligibility
3428 Were enrolled and underwent
randomization
855 Were assigned to receive
dihydroartemisinin–piperaquine
and included in safety
population
849 Were assigned to receive
mefloquine–artesunate
and included in safety
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853 Were included in efficacy
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848 Were included in efficacy
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881 Were assigned to receive
artemether–lumefantrine
and included in safety
population
843 Were assigned to receive
amodiaquine–artesunate
and included in safety
population
1 Was excluded after
first dose
1 Was excluded after
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2 Were excluded after
first dose
1 Was excluded after
first dose
880 Were included in efficacy
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842 Were included in efficacy
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759 Were included in intention-
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770 Were included in intention-
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50 Were excluded 51 Were excluded 94 Were excluded 78 Were excluded
830 Were included in intention-
to-treat population
791 Were included in intention-
to-treat population
720 Were included in
per-protocol population
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per-protocol population
2 Did not meet
inclusion 
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15 Had treatment
violation
53 Had follow-up
violation
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60 Had follow-up
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1 Did not meet
inclusion 
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94 Had follow-up
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inclusion 
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26 Had treatment
violation
87 Had follow-up
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810 Were included in
per-protocol population
742 Were included in
per-protocol population
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with artemether–lumefantrine than among women 
treated with the other therapies; at day 1 after the start of  
treatment, 24.8% of  the women (217 of  875 women) in 
the artemether–lumefantrine group still had detectable 
parasitemia, as compared with 6.9% (57 of  828) in the 
amodiaquine–artesunate group, 8.0% (67 of  837) in the 
dihydroartemisinin–piperaquine group, and 13.5% (113 of  
837) in the mefloquine–artesunate group (P<0.001).
Gametocyte prevalence at enrollment was low (Table 1), with 
a median density between 11 and 40 gametocytes per cubic 
millimeter. Gametocyte carriage remained low throughout 
follow-up, with no significant difference among the treatment 
groups. Similarly, changes in the hemoglobin level did not 
differ significantly among the treatment groups throughout 
follow-up (Fig. S2 in the Supplementary Appendix).
The prevalence of  placental malaria infection at delivery was 
similar among the treatment groups (P = 0.47). The mean birth 
weight of  the babies, after adjustment according to country, 
was similar among the treatment groups. The mean (±SD) 
birth weight was 2854±449 g in the artemether–lumefantrine 
group, 2880±452 g in the amodiaquine–artesunate group, 
2901±454 g in the dihydroartemisinin–piperaquine group, 
and 2875±433 g in the mefloquine–artesunate group (P 
= 0.40). Similarly, the percentage of  babies with low birth 
weight did not vary significantly among the treatment 
groups (17.2% in the artemether–lumefantrine group, 
15.5% in the amodiaquine–artesunate group, 14.1% in the 
dihydroartemisinin–piperaquine group, and 15.2% in the 
mefloquine–artesunate group; P = 0.32).
Safety
A total of  72 women had serious adverse events during the 
63-day follow-up, including 1 woman in the mefloquine–
artesunate group who died approximately 1 month after 
treatment, probably from meningitis (Table S9 in the 
Supplementary Appendix). There were 10 serious adverse 
events that were assessed by the site investigator as being 
probably related to the study medication, including 5 in the 
amodiaquine–artesunate group (anemia in 2 women, upper 
n engl j med 374;10 nejm.org March 10, 2016918
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third of the women, and few women (6.1%) had 
fever at the time of recruitment.
Treatment Efficacy
The large majority of treatment failures were late 
parasitologic failures, with fewer women having 
a late clinical failure (Table 2). Most cases of late 
treatment failures were classified as new infec-
tions.
According to the per-protocol analysis, the 
overall PCR-adjusted cure rate at day 63 was 
94.8% (95% confidence interval [CI], 93.0 to 
Characteristic
Artemether– 
Lumefantrine 
(N = 880)
Amodiaquine– 
Artesunate 
(N = 842)
Dihydroartemisinin– 
Piperaquine 
(N = 853)
Mefloquine– 
Artesunate 
(N = 848)
Country (no.)
Burkina Faso 290 291 0 288
Ghana 0 261 265 260
Malawi 290 290 288 0
Zambia 300 0 300 300
Age (yr) 22.6±5.6 23.4±5.9 22.3±5.4 23.5±5.9
Symptomatic malaria (%)† 37.2 34.9 37.4 43.8
Fever (%) 6.5 6.8 3.2 8.0
Parasite density >2000/mm3 (%) 30.6 25.3 29.1 32.1
≥3 symptoms (%)‡ 7.2 9.3 11.8 14.3
Gametocytes present (%) 2.4 2.9 2.5 0.7
Parasite density (per mm3)
Median 800 569 680 840
Interquartile range 213–2880 165–2025 200–2760 218–3040
Hemoglobin (g/dl)
Median 10.2 10.1 10.1 10.1
Interquartile range 9.2–11.0 9.1–11.0 9.1–11.0 9.1–10.9
Gravidity (%)
1 36.3 37.4 40.0 32.7
2 23.1 22.2 25.3 23.7
≥3 40.6 40.4 34.7 43.6
Trimester of gestation (%)§
Second 71.8 75.0 68.5 65.8
Third 28.2 24.9 31.5 34.2
Bed net used before trial entry (%) 34.4 34.6 27.9 37.5
Insecticide-treated bed net used before 
trial entry (%)¶
24.8 23.9 17.1 27.9
Use of intermittent preventive treatment 
before day 0 (%)
9.9 10.9 13.7 16.4
*  Plus–minus values are means ±SD. There were no significant differences at baseline among the treatment groups.
†  Symptomatic malaria was defined as any of the following: fever (axillary temperature, ≥37.5°C) at baseline with parasit-
emia of any density; a parasite count of more than 2000 per cubic millimeter, regardless of symptoms; or at least three 
of the following symptoms — fever in the previous 24 hours, weakness or fatigue, muscle or joint aches, headache, or 
convulsion — with parasitemia of any density.
‡  Symptoms included fever in the previous 24 hours, weakness or fatigue, muscle or joint aches, or headache.
§  One woman in the amodiaquine–artesunate group was included in the trial during the first trimester of pregnancy.
¶  Women were provided with an insecticide-treated bed net at the start of the trial.
Table 1. Characteristics of the Participants at Baseline.*
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(Table 3). Adverse events that were related to the 
treatment, as determined by the investigators, 
occurred significantly more frequently in the 
mefloquine–artesunate group (in 50.6% of women; 
430 of 850 women) and the amodiaquine–arte-
sunate group (in 48.5%; 408 of 842) than in the 
dihydroartemisinin–piperaquine group (in 20.6%; 
176 of 855) and the artemether–lumefantrine 
group (in 11.5%; 101 of 881) (P<0.001 for the 
comparison among the four groups). This result 
was due mainly to the higher occurrence of 
asthenia, poor appetite, dizziness, nausea, and 
vomiting among women treated with meflo-
quine–artesunate or amodiaquine–artesunate 
than among those treated with dihydroartemis-
inin–piperaquine or artemether–lumefantrine 
(Table 3).
Behavioral changes were observed in 4 women, 
of whom 2 were in the amodiaquine–artesunate 
group (changes noted on day 2 and day 3 after 
treatment), 1 was in the mefloquine–artesunate 
group (changes noted on day 2 after treatment), 
and 1 was in the artemether–lumefantrine group 
(changes noted on day 60 after treatment); the 
two behavioral changes in the amodiaquine–
artesunate group were considered by the site 
investigator to be possibly related to treatment. 
All the women recovered completely. A woman 
Variable
Artemether– 
Lumefantrine 
(N = 880)
Amodiaquine– 
Artesunate 
(N = 842)
Dihydroartemisinin– 
Piperaquine 
(N = 853)
Mefloquine– 
Artesunate 
(N = 848)
Efficacy outcome — no. (%)†
Early treatment failure 0 2 (0.2) 1 (0.1) 0
Development of danger signs or severe 
malaria
0 0 1 (0.1) 0
Rescue treatment on any of days 0–3 0 1 (0.1) 0 0
Parasitemia on day 3 ≥ day 0 0 1 (0.1) 0 0
Late clinical failure 26 (3.0) 13 (1.5) 6 (0.7) 28 (3.3)
Recrudescence 4 (0.5) 2 (0.2) 1 (0.1) 8 (0.9)
New infection 21 (2.4) 10 (1.2) 5 (0.6) 18 (2.1)
Indeterminate or sample unavailable 1 (0.1) 1 (0.1) 0 2 (0.2)
Late parasitologic failure 362 (41.1) 123 (14.6) 91 (10.7) 176 (20.8)
Recrudescence 37 (4.2) 9 (1.1) 5 (0.6) 17 (2.0)
New infection 303 (34.4) 100 (11.9) 71 (8.3) 144 (17.0)
Indeterminate or sample unavailable 22 (2.5) 14 (1.7) 15 (1.8) 15 (1.8)
Adequate clinical and parasitologic response 436 (49.5) 642 (76.2) 653 (76.6) 557 (65.7)
Response could not be determined 56 (6.4) 62 (7.4) 102 (12.0) 87 (10.3)
Received rescue treatment but had no 
infection
6 (0.7) 11 (1.3) 8 (0.9) 9 (1.1)
Died‡ 0 0 0 1 (0.1)
Lost to follow-up or withdrew 50 (5.7) 51 (6.1) 94 (11.0) 77 (9.1)
Treatment success§
Per-protocol analysis
PCR-adjusted
No. of patients 789 729 707 716
Rate — % (95% CI) 94.8 (93.0–96.1) 98.5 (97.3–99.2) 99.2 (98.2–99.6) 96.8 (95.2–97.9)
PCR-unadjusted
No. of patients 810 742 720 728
Rate — % (95% CI) 52.5 (49.0–55.9) 82.3 (79.4–84.9) 86.9 (84.3–89.2) 73.8 (70.4–76.8)
Table 2. Efficacy Outcomes and Treatment Success Rates.*
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treated with amodiaquine–artesunate reported 
hallucinations on day 3 after treatment; these 
were considered by the investigator to be possi-
bly related to treatment. The woman recovered 
completely. Significantly more women in the 
amodiaquine–artesunate group than in the other 
three groups reported insomnia: 4.0% (34 of 
842 women) in the amodiaquine–artesunate group 
versus 2.5% (21 of 850) in the mefloquine–arte-
sunate group, 1.6% (14 of 855) in the dihydroar-
temisinin–piperaquine group, and 0.3% (3 of 881) 
in the artemether–lumefantrine group (P = 0.04).
The pulse rate and blood pressure tended to be 
lower among women treated with amodiaquine–
artesunate than among those in the other three 
groups (Figs. S3 and S4 in the Supplementary 
Appendix). The percentage of women with a dia-
stolic blood pressure of less than 50 mm Hg and 
a systolic blood pressure of less than 90 mm Hg 
was higher in the amodiaquine–artesunate group 
than in the other groups (P<0.001). Similarly, 
the percentage of women with a pulse rate of 
less than 60 beats per minute appeared to be 
higher in the amodiaquine–artesunate group 
than in the other groups, but this difference was 
not significant (P = 0.40). Hypotension or a low 
diastolic blood pressure as an adverse event (i.e., 
considered by the local investigator to be clini-
cally significant) occurred more frequently in the 
amodiaquine–artesunate group (1.5%) than in 
the other treatment groups (range, 0.6 to 0.8%). 
There were no significant differences in the 
laboratory safety values among the treatment 
groups.
Outcome of Pregnancy
There were 13 miscarriages (1 miscarriage in the 
artemether–lumefantrine group and 4 in each of 
the other three groups). There were 78 stillbirths 
overall, with 16 stillbirths occurring in 856 
births (1.9%) in the artemether–lumefantrine 
group, 17 in 815 (2.1%) in the amodiaquine–
Variable
Artemether– 
Lumefantrine 
(N = 880)
Amodiaquine– 
Artesunate 
(N = 842)
Dihydroartemisinin– 
Piperaquine 
(N = 853)
Mefloquine– 
Artesunate 
(N = 848)
Intention-to-treat analysis
PCR-adjusted
No. of patients 807 776 744 753
Rate — % (95% CI) 94.2 (92.3–954.6) 96.9 (95.4–97.9) 98.0 (96.7–98.8) 95.5 (93.8–96.8)
PCR-unadjusted
No. of patients 830 791 759 770
Rate — % (95% CI) 52.5 (49.1–55.9) 81.2 (78.3–83.7) 86.0 (83.4–88.3) 72.3 (69.1–73.4)
*  CI denotes confidence interval.
†  Early treatment failure was defined as one of the following: the development of danger signs or severe malaria or worsening of clinical con-
ditions on day 0, 1, 2, or 3 in the presence of parasitemia; parasitemia on day 3 that was the same as or greater than the count on day 0;  
or parasitemia on day 3 and fever (axillary temperature, ≥37.5°C). Late clinical failure was defined as the either the development of danger 
signs or severe malaria or worsening of clinical conditions on any day after day 3 in the presence of parasitemia, without the patient having 
previously met any of the criteria for early treatment failure, or the presence of parasitemia and fever on any day after day 3, without the pa-
tient having previously met the criteria for early treatment failure. Late parasitologic failure was defined as the presence of parasitemia after 
day 3 and an axillary temperature of less than 37.5°C, without the patient having previously met any of the criteria of early treatment failure 
or late clinical failure. An adequate clinical and parasitologic response was defined as the absence of parasitemia at the end of the follow-up 
period (day 63), regardless of the axillary temperature, without the patient having previously met any of the criteria of early treatment failure 
or late clinical or parasitologic failure. In the polymerase-chain-reaction (PCR)–adjusted estimates, patients with late asexual-parasite reap-
pearance (with or without fever) were considered to have had an adequate clinical and parasitologic response if the PCR analysis showed a 
new infection rather than a recrudescence.
‡  The one death that occurred during the trial was not considered by the investigators to be related to malaria or to treatment (probably due 
to meningitis).
§  In the estimation of the PCR-adjusted cure rate, only recurrent infections that were shown to be the same as those before treatment were 
considered to be treatment failures. Conversely, for the estimation of the PCR-unadjusted cure rate, all recurrent infections were considered 
to be treatment failures. If the difference in the true (PCR-adjusted) cure rates was less than 5 percentage points, the treatments were con-
sidered to be therapeutically equivalent. Treatment success rates according to country are provided in Tables S7 (per-protocol analysis) and 
S8 (intention-to-treat analysis) in the Supplementary Appendix.
Table 2. (Continued.)
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or amodiaquine–artesunate than among those treated with 
dihydroartemisinin–piperaquine or artemether–lumefantrine 
(Table 3).
Behavioral changes were observed in 4 women, of  whom 2 
were in the amodiaquine–artesunate group (changes noted 
on day 2 and day 3 after treatment), 1 was in the mefloquine–
artesunate group (changes noted on day 2 after treatment), 
and 1 was in the artemether–lumefantrine group (changes 
noted on day 60 after treatment); the two behavioral changes 
in the amodiaquine–artesunate group were considered by 
the site investigator to be possibly related to treatment. 
All the women recovered completely. A woman treated 
with amodiaquine–artesunate reported hallucinations 
on day 3 after treatment; these were considered by the 
investigator to be possibly related to treatment. The woman 
recovered completely. Significantly more women in the 
amodiaquine–artesunate group than in the other three 
groups reported insomnia: 4.0% (34 of  842 women) in the 
amodiaquine–artesunate group versus 2.5% (21 of  850) in 
the mefloquine–artesunate group, 1.6% (14 of  855) in the 
dihydroartemisinin–piperaquine group, and 0.3% (3 of  881) 
in the artemether–lumefantrine group (P = 0.04).
The pulse rate and blood pressure tended to be lower 
among women treated with amodiaquine–artesunate than 
among those in the other three groups (Figs. S3 and S4 in 
the Supplementary Appendix). The percentage of  women 
abdominal pain in 1, and malaise in 2), 4 in the mefloquine–
artesunate group (abdominal pain in 1, vomiting in 2, and 
malaise in 1), and 1 in the dihydroartemisinin–piperaquine 
group (a possible adverse drug reaction with headache and 
general weakness 2 days after the completion of  treatment; 
the woman recovered completely). No significant difference 
in the occurrence of  serious adverse events was found 
among the treatment groups.
Women treated with mefloquine–artesunate and those 
treated with amodiaquine–artesunate had a significantly 
higher incidence of  any adverse event (84.9% [722 of  850 
women] and 79.0% [665 of  842], respectively) than did 
those in the artemether–lumefantrine group (72.8%; 641 
of  881) and those in the dihydroartemisinin–piperaquine 
group (70.4%; 602 of  855) (P<0.001 for the comparison 
among the four groups) (Table 3). Adverse events that were 
related to the treatment, as determined by the investigators, 
occurred significantly more frequently in the mefloquine–
artesunate group (in 50.6% of  women; 430 of  850 women) 
and the amodiaquine–artesunate group (in 48.5%; 408 of  
842) than in the dihydroartemisinin–piperaquine group (in 
20.6%; 176 of  855) and the artemether–lumefantrine group 
(in 11.5%; 101 of  881) (P<0.001 for the comparison among 
the four groups). This result was due mainly to the higher 
occurrence of  asthenia, poor appetite, dizziness, nausea, and 
vomiting among women treated with mefloquine–artesunate 
n engl j med 374;10 nejm.org March 10, 2016922
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artesunate group, 22 in 818 (2.7%) in the dihy-
droartemisinin–piperaquine group, and 23 in 821 
(2.8%) in the mefloquine–artesunate group. The 
proportion of live births did not differ signifi-
cantly among the treatment groups (P = 0.85). 
The percentage of preterm babies, as determined 
by the total Ballard score, was 10.2% in the arte-
mether–lumefantrine group, 3.4% in the amo-
diaquine–artesunate group, 9.5% in the dihydro-
artemisinin–piperaquine group, and 7.7% in the 
mefloquine–artesunate group (P = 0.64). A total 
of 44 congenital malformations were observed, 
with 17 occurring in 832 newborns (2.0%) in the 
artemether–lumefantrine group, 8 in 776 (1%) in 
the amodiaquine–artesunate group, 6 in 767 
(0.8%) in the dihydroartemisinin–piperaquine 
group, and 13 in 780 (1.7%) in the mefloquine–
artesunate group.
Discussion
The PCR-adjusted cure rates were in the range of 
94.8 to 99.2% for all four artemisinin-based 
combination therapies, and the differences among 
them were within the prespecified equivalence 
margin of 5 percentage points. The high success 
Figure 2. Differences in PCR-Adjusted and PCR-Unadjusted Treatment Success Rates at Day 63, According to Pairwise Analysis  
and Country.
In the estimation of the polymerase-chain-reaction (PCR)–adjusted cure rate, only recurrent infections that were shown by means of 
 genotyping to be the same infections as those before treatment (recrudescences) were considered to be treatment failures. Conversely, 
for the estimation of the PCR-unadjusted cure rate, all recurrent infections were considered to be treatment failures. A positive value in 
the difference reflects a higher cure rate in the treatment listed first. If the difference in the cure rates was less than 5 percentage points 
(red lines), the treatments were considered to be therapeutically equivalent. Dashed horizontal lines indicate the 95% confidence inter-
vals for the comparisons of treatment groups within a single country; solid horizontal lines are used for comparisons of total data from 
two countries.
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There were 13 miscarriages (1 miscarriage in the artemether–
lumefantrine group and 4 in each of  the other three groups). 
There were 78 stillbirths overall, with 16 stillbirths occurring 
in 856 births (1.9%) in the artemether–lumefantrine group, 
17 in 815 (2.1%) in the amodiaquine–artesunate group, 22 
in 818 (2.7%) in the dihydroartemisinin–piperaquine group, 
and 23 in 821 (2.8%) in the mefloquine–artesunate group. 
The proportion of  live births did not differ significantly 
among the treatment groups (P = 0.85). The percentage 
of  preterm babies, as determined by the total Ballard 
score, was 10.2% in the artemether–lumefantrine group, 
3.4% in the amodiaquine–artesunate group, 9.5% in the 
dihydroartemisinin–piperaquine group, and 7.7% in the 
mefloquine–artesunate group (P = 0.64). A total of  44 
with a diastolic blood pressure of  less than 50 mm Hg and a 
systolic blood pressure of  less than 90 mm Hg was higher in 
the amodiaquine–artesunate group than in the other groups 
(P<0.001). Similarly, the percentage of  women with a pulse 
rate of  less than 60 beats per minute appeared to be higher 
in the amodiaquine–artesunate group than in the other 
groups, but this difference was not significant (P = 0.40). 
Hypotension or a low diastolic blood pressure as an adverse 
event (i.e., considered by the local investigator to be clinically 
significant) occurred more frequently in the amodiaquine–
artesunate group (1.5%) than in the other treatment groups 
(range, 0.6 to 0.8%). There were no significant differences 
in the laboratory safety values among the treatment groups.
Outcome of pregnancy
n engl j med 374;10 nejm.org March 10, 2016924
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Event
Artemether– 
Lumefantrine 
(N = 881)
Amodiaquine– 
Artesunate 
(N = 842)
Dihydroartemisinin– 
Piperaquine 
(N = 855)
Mefloquine– 
Artesunate 
(N = 850)
percent of patients
Any serious adverse event during 63 days 
of follow-up
0.7 2.6 2.1 2.9
Mild 0 0.2 0.2 0.5
Moderate 0.2 1.3 1.2 1.5
Severe 0.2 0.7 0.5 0.5
Life-threatening 0.2 0.4 0.2 0.5
Specific serious adverse event during 63 days 
of follow-up
Blood disorder 0 0.7 0.2 0
Moderate 0 0.2 0 0
Severe 0 0.4 0.2 0
Life-threatening 0 0.1 0 0
Moderate abdominal pain 0 0.2 0 0.1
Severe diarrhea 0.1 0 0 0
Vomiting 0 0 0 0.2
Moderate 0 0 0 0.1
Severe 0 0 0 0.1
Malaise 0 0.2 0 0.1
Mild 0 0.2 0 0
Moderate 0 0 0 0.1
Moderate adverse drug reaction 0 0 0.1 0
Infection 0.5 1.0 1.1 1.5
Mild 0 0 0.2 0.2
Moderate 0.2 0.8 0.8 0.9
Severe 0 0.1 0 0.2
Life-threatening 0.2 0 0 0.1
Complications of pregnancy and delivery 0.1 0.5 0.5 0.7
Mild 0 0.1 0 0
Moderate 0 0 0.1 0.2
Severe 0.1 0.1 0.1 0.1
Life-threatening 0 0.2 0.2 0.4
Mild asthma 0 0 0 0.1
Any adverse event during 63 days of follow-up 72.8 79.0 70.4 84.9
Mild 54.4 56.7 59.1 68.8
Moderate 18.2 21.5 11.1 15.2
Severe 0.1 0.7 0.2 0.8
Life-threatening 0.1 0.1 0 0.1
Any event during first 7 days 24.3 59.5 34.2 60.7
Table 3. Safety Outcomes.
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the WHO. Nevertheless, the cure rates in the artemether–
lumefantrine group were significantly lower than those 
in the groups that received the other artemisinin-based 
combination therapies, which had similar high efficacy. 
In a previous trial in Uganda, the efficacy of  artemether–
lumefantrine (until day 42) during pregnancy was 99.3%.12 
The longer follow-up until day 63 in our trial cannot explain 
the lower cure rates in our trial than in the Uganda trial, 
because most treatment failures occurred between day 
28 and day 42 (Fig. S1 in the Supplementary Appendix). 
The efficacy of  artemether–lumefantrine was low (82%) 
among pregnant women at the Thai–Burmese border,13 
congenital malformations were observed, with 17 occurring 
in 832 newborns (2.0%) in theartemether–lumefantrine 
group, 8 in 776 (1%) in the amodiaquine–artesunate group, 6 
in 767 (0.8%) in the dihydroartemisinin–piperaquine group, 
and 13 in 780 (1.7%) in the mefloquine–artesunate group.
Discussion
The PCR-adjusted cure rates were in the range of  94.8 to 
99.2% for all four artemisinin-based combination therapies, 
and the differences among them were within the prespecified 
equivalence margin of  5 percentage points. The high success 
rates are remarkable given the long follow-up period, which 
was 3 weeks longer than the 6 weeks recommended by 
n engl j med 374;10 nejm.org March 10, 2016 925
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Event
Artemether– 
Lumefantrine 
(N = 881)
Amodiaquine– 
Artesunate 
(N = 842)
Dihydroartemisinin– 
Piperaquine 
(N = 855)
Mefloquine– 
Artesunate 
(N = 850)
percent of patients
Any drug-related event 11.5 48.5 20.6 50.6
Mild 10.1 37.1 18.4 41.9
Moderate 1.2 11.2 2.1 8.2
Severe 0.1 0.2 0.1 0.5
Specific drug-related adverse event*
Abdominal pain 2.7 7.1 2.1 5.3
Mild 2.2 6.3 2.0 4.2
Moderate 0.6 0.8 0.1 1.1
Asthenia 1.8 26.6 6.8 14.2
Mild 1.6 16.7 6.0 10.4
Moderate 0.2 9.9 0.8 3.5
Severe 0 0 0 0.4
Decreased appetite 0.3 8.2 2.1 7.1
Mild 0.3 7.1 2.0 6.6
Moderate 0 1.1 0.1 0.5
Dizziness 1.2 23.5 1.6 30.6
Mild 1.2 16.2 1.4 24.2
Moderate 0 7.2 0.2 6.2
Severe 0 0.1 0 0.1
Headache 4.3 6.3 5.1 7.5
Mild 3.7 4.8 4.4 6.6
Moderate 0.6 1.5 0.7 0.9
Musculoskeletal pain 0.8 7.2 2.6 4.5
Mild 0.8 5.8 2.3 3.2
Moderate 0 1.4 0.2 1.2
Severe 0 0 0 0.1
Nausea 0.9 11.5 4.0 13.9
Mild 0.9 10.6 3.7 12.6
Moderate 0 1.0 0.2 1.3
Vomiting 0.9 15.9 5.7 18.9
Mild 0.8 12.5 5.1 13.5
Moderate 0.1 3.4 0.6 5.4
Abnormality in vital sign during treatment†
Pulse rate <60 beats/min 1.1 2.1 1.6 1.5
Diastolic blood pressure <50 mm Hg 8.4 15.1 7.7 4.7
Systolic blood pressure <90 mm Hg 5.1 12.2 6.3 4.1
*  The specific drug-related adverse events reported here were those that occurred in more than 5% of the patients in at least one treatment group.
†  Abnormality in vital signs during treatment was assessed during days 1, 2, and 3; the percentage of patients shown is the percentage of 
those with an abnormality on any of these days.
Table 3. (Continued.)
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onset of  treatment, one in the mefloquine–artesunate group 
and two in the amodiaquine–artesunate group. Mefloquine 
use has been associated with neuropsychiatric adverse 
events,29 a phenomenon that has also been described for 
4-aminoquinolines.6
In conclusion, artemether–lumefantrine was associated 
with the fewest adverse effects and with acceptable cure 
rates but provided the shortest post-treatment prophylaxis. 
Dihydroartemisinin–piperaquine had the best efficacy and 
an acceptable safety profile.
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